TickerFacts.

Idexx Laboratories Inc (IDXX): Cash & Equivalents

Annual figures by period end, from SEC filings.

$180.07M
As of 2025-12-31
$196.93M
As of 2026-06-30
+17.0%
3-year compound annual growth
-14.1%
5-year compound annual growth
+3.4%
10-year compound annual growth
$453.93M2008-12-31: $78.87M2009-12-31: $106.73M2010-12-31: $156.91M2011-12-31: $183.90M2012-12-31: $223.99M2013-12-31: $279.06M2014-12-31: $322.54M2015-12-31: $128.99M2016-12-31: $154.90M2017-12-31: $187.68M2018-12-31: $123.79M2019-12-31: $90.33M2020-12-31: $383.93M2021-12-31: $144.45M2022-12-31: $112.55M2023-12-31: $453.93M2024-12-31: $288.27M2025-12-31: $180.07M$180.07M
2008-12-31 Cash & Equivalents (USD) 2025-12-31
Period endedCash & EquivalentsChange YoYSource filing
2025-12-31$180.07M-37.5%2026-02-20, Balance as of period end
2024-12-31$288.27M-36.5%2026-02-20, Balance as of period end
2023-12-31$453.93M+303.3%2025-02-21, Balance as of period end
2022-12-31$112.55M-22.1%2024-02-22, Balance as of period end
2021-12-31$144.45M-62.4%2023-02-16, Balance as of period end
2020-12-31$383.93M+325.0%2022-02-16, Balance as of period end
2019-12-31$90.33M-27.0%2021-02-12, Balance as of period end
2018-12-31$123.79M-34.0%2020-02-14, Balance as of period end
2017-12-31$187.68M+21.2%2019-02-15, Balance as of period end
2016-12-31$154.90M+20.1%2019-02-15, Balance as of period end
2015-12-31$128.99M-60.0%2018-02-16, Balance as of period end
2014-12-31$322.54M+15.6%2017-02-17, Balance as of period end
2013-12-31$279.06M+24.6%2016-02-17, Balance as of period end
2012-12-31$223.99M+21.8%2015-02-17, Balance as of period end
2011-12-31$183.90M+17.2%2014-02-18, Balance as of period end
2010-12-31$156.91M+47.0%2013-02-19, Balance as of period end
2009-12-31$106.73M+35.3%2012-02-17, Balance as of period end
2008-12-31$78.87Mn/a2011-02-22, Balance as of period end

Cash & Equivalents at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCash & EquivalentsChange YoY
Idexx Laboratories Inc (IDXX)2025-12-31$180.07M-37.5%
QuidelOrtho Corp (QDEL)2025-12-28$169.80M+72.7%
Lantheus Holdings, Inc. (LNTH)2025-12-31$359.12M-60.7%
Neogen Corp (NEOG)2026-05-31$185.50M+43.8%
Myriad Genetics Inc (MYGN)2025-12-31$149.60M+46.1%
Intellia Therapeutics, Inc. (NTLA)2025-12-31$155.46M-17.8%
Alpha Teknova, Inc. (TKNO)2025-12-31$5.91M+59.4%
Immucell Corp (ICCC)2025-12-31$3.81M+1.3%
Aspira Women's Health Inc. (AWHL)2025-12-31$1.75M-0.8%

Compare IDXX, QDEL, LNTH, NEOG side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗